PharmaShots Weekly Snapshots (July 25 – 29, 2022)
Published: July 29, 2022 | Tags: BMS, Opdivo, nivolumab, Yervoy, ipilimumab, Renal Cell Carcinoma, Clinical Trial, P-III CheckMate -914 Trial
Published: July 29, 2022 | Tags: Ionis, Fesomersen, End-Stage Renal Disease, Hemodialysis, Clinical Trial, P-IIb RE-THINC ESRD Study
NeuroSense Collaborated with NeuraLight to Advance ALS Oculometric Biomarkers Using AI and ML
Published: July 29, 2022 | Tags: NeuroSense, NeuraLight, ALS, Oculometric Biomarkers, Biotech, AI, ML, P-IIb (PARADIGM) trial, PrimeC
Published: July 29, 2022 | Tags: AbbVie, Rinvoq, upadacitinib, EC, Approval, Active Non-Radiographic Axial Spondyloarthritis
Novartis’ Beovu (brolucizumab) Receives NICE Recommendation for Diabetic Macular Oedema
Published: July 29, 2022 | Tags: Novartis, Beovu, brolucizumab, NICE, Diabetic Macular Oedema, Regulatory, P-III KESTREL, KITE Trials
Published: July 29, 2022 | Tags: Elevation, CSPC, EO-3021, SYSA1801, Solid Tumors, Pharma
Published: July 28 2022 | Tags: Organon, Cirqle Biomedical, Non-hormonal, Contraceptive Therapy, Pharma
Published: July 28 2022 | Tags: Palisade Bio, LB1148, Postoperative, Bowel Function, Clinical Trial, P-III Study
Published: July 28 2022 | Tags: Eliaz, Terumo Blood and Cell Technologies, Novel Therapeutic Apheresis Treatment, Acute Kidney Injury, Sepsis-Induced Acute Kidney Injury, Pharma
Published: July 28 2022 | Tags: AbbVie, US, FDA, EMA, Rinvoq, upadacitinib, Crohn's Disease, Pharma
Lexicon Reports the US FDA’s Acceptance of NDA for Sotagliflozin to Treat Heart Failure
Published: July 28 2022 | Tags: Lexicon, Sotagliflozin, Heart Failure, Regulatory US, FDA, NDA
Published: July 28 2022 | Tags: Cidara, Melinta, Rezafungin, US, Candidemia, Invasive Candidiasis, Pharma
Published: July 27 2022 | Tags: IDEAYA, Amgen, IDE397, AMG 193, MTAP Deleted, Solid Tumors, Pharma
Published: July 27 2022 | Tags: Moleculera Labs, General Genomics, Personalized Therapies, Autoimmune Neuropsychiatric Disorders, AI, Pharma
Published: July 27 2022 | Tags: GBT, Oxbryta, voxelotor, Hemolytic Anemia, Sickle Cell, Regulatory MHRA, Marketing Authorization, Great Britain
Published: July 27 2022 | Tags: Janssen, Rybrevant, amivantamab-vmjw, Non-Small Cell Lung Cancer, EGFR Mutations, Clinical Trial, P-Ib/II, CHRYSALIS-2 Study, IASLC 2022,
Published: July 27 2022 | Tags: AbbVie, Rinvoq, upadacitinib, Ulcerative Colitis, Regulatory, EC, Approval
Published: July 27 2022 | Tags: Kelun-Biotech, MSD, ADC, SKB-264, Solid Tumors, Biotech
Published: July 26 2022 | Tags: Ionis, Tofersen, Superoxide Dismutase 1 Amyotrophic Lateral Sclerosis, Regulatory, US, FDA, NDA, Priority Review
Published: July 26 2022 | Tags: Seagen, Astellas, Padcev, enfortumab vedotin-ejfv, Keytruda, pembrolizumab, Urothelial Cancer, Clinical Trial, P-Ib/II, EV-103 Cohort K Trial
Published: July 26 2022 | Tags: ReCor Medical, Otsuka Medical Devices, Paradise uRDN System, Hypertension, MedTech, RADIANCE II US Trial
Published: July 26 2022 | Tags: BridgeBio Pharma, Sentynl, Nulibry, fosdenopterin, MoCD Type A, Regulatory, CHMP
Published: July 26 2022 | Tags: Lepu, Hanx Biopharmaceuticals, Puyouheng, HX-008, Solid Tumors, Regulatory, NMPA, Approval
NewAmsterdam Pharma to Go Public via FLAC SPAC Merger for ~$326M
Published: July 26 2022 | Tags: NewAmsterdam Pharma, obicetrapib, cardiovascular disease, M&A, Public, FLAC, SPAC Merger, ~$326M
Ginkgo to Acquire Zymergen for ~$300M
Published: July 25 2022 | Tags: Ginkgo, Zymergen, M&A, Acquire, ~$300M, Horizontal Synthetic Biology Platform
Rona Therapeutics Collaborated with Sanofi for siRNA Therapeutic Portfolio and Technology Platform
Published: July 25 2022 | Tags: Rona Therapeutics, Sanofi, siRNA Therapeutic, Technology Platform, Pharma
Published: July 25 2022 | Tags: Kite, Tecartus, brexucabtagene autoleucel, Acute Lymphoblastic Leukemia, Regulatory, CHMP
Published: July 25 2022 | Tags: Daiichi Sankyo, AstraZeneca, Enhertu, HER2 Low Metastatic Breast Cancer, Regulatory, US, FDA, sBLA, Priority Review
Published: July 25 2022 | Tags: Sandoz, Hyrimoz, biosimilar, adalimumab, Inflammatory Diseases, Regulatory, US, FDA, sBLA
Published: July 25 2022 | Tags: Alnylam, Vutrisiran, hATTR Amyloidosis, Polyneuropathy, Regulatory, CHMP, EMA
Related Post: PharmaShots Weekly Snapshots (July 18 – 22, 2022)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.